Anti-poliovirus activity of protease in hibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid in hibitor compounds

Antiviral Research

Volumn 98, Issue 2, 2013, Pages 186-191

  Rhoden, Eric ^a   Liu, Hong Mei ^a   Wang Chern, Shur wern ^a   Oberste, M Steven ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Antiviral compounds; Capsid in hibitors; Capsid inhibitors; Global polio eradication initiative; Poliomyelitis; Poliovirus; Protease in hibitors; Protease inhibitors

Indexed keywords

AG 7404; ANTIVIRUS AGENT; POLIOMYELITIS VACCINE; UNCLASSIFIED DRUG; V 073; VAPENDAVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; DRUG POTENTIATION; DRUG SENSITIVITY; IN VITRO STUDY; NONHUMAN; POLIOMYELITIS VIRUS 1; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS STRAIN;

MIRIDAE; POLIOVIRUS;

EID: 84875995705     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.03.003     Document Type: Article

References (45)

1. Buontempo, P.J.,Cox,S.,Wright-Minogue,J.,DeMartino,J.L.,Skelton,A.M.,Ferrari, E., Albin,R.,Rozhon,E.J.,Girijavallabhan,V.,Modlin,J.F.,O'Connell,J.F.,1997. SCH 48,973: apotent, broad-spectrum, antienterovirus compound. Antimicrob. Agents Chemother. 41,1220-1225.
2. Buontempo P.J., Cox S., Wright-Minogue J., De Martino J.L., Skelton A.M., Ferrari E., Albin R., Rozhon E.J., Girijavallabhan V., Modlin J.F., O'Connell J.F. SCH 48,973: a potent, broad-spectrum, antienterovirus compound. Antimicrob. Agents Chemother. 1997, 41:1220-1225.
3. Collett, M.S.,Neyts,J.,Modlin,J.F.,2008. A case for developing antiviral drugs against polio. Antiviral Res.79,179-187.
4. Collett M.S., Neyts J., Modlin J.F. A case for developing antiviral drugs against polio. Antiviral Res. 2008, 79:179-187.
5. De Palma,A.M.,Pürstinger,G.,Wimmer,E.,Patick,A.K.,Andries,K.,Rombaut,B.,De Clercq, E.,Neyts,J.,2008a. Potential use of Antiviral agents in polio eradication. Emerg. Infect.Dis.14,545-551.
6. De Palma A.M., Pürstinger G., Wimmer E., Patick A.K., Andries K., Rombaut B., De Clercq E., Neyts J. Potential use of antiviral agents in polio eradication. Emerg. Infect. Dis. 2008, 14:545-551.
7. De Palma,A.M.,Vliegen,I.,DeClercq,E.,Neyts,J.,2008b.Selective in hibitors of picornavirus replication. Med.Res.Rev.28,823-884.
8. De Palma A.M., Vliegen I., De Clercq E., Neyts J. Selective inhibitors of picornavirus replication. Med. Res. Rev. 2008, 28:823-884.
9. Dragovich, P.S.,Prins,T.J.,Zhou,R.,Johnson,T.O.,Hua,Y.,Luu,H.T.,Sakata,S.K., Brown, E.L.,Maldonado,F.C.,Tuntland,T.,Lee,C.A.,Fuhrman,S.A.,Zalman,L.S., Patick, A.K.,Matthews,D.A.,Wu,E.Y.,Guo,M.,Borer,B.C.,Nayyar,N.K.,Moran, T., Chen,L.,Rejto,P.A.,Rose,P.W.,Guzman,M.C.,Dovalsantos,E.Z.,Lee,S., McGee, K.,Mohajeri,M.,Liese,A.,Tao,J.,Kosa,M.B.,Liu,B.,Batugo,M.R., Gleeson, J.P.,Wu,Z.P.,Liu,J.,Meador 3rd,J.W.,Ferre,R.A.,2003.Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease in hibitors. 8. Pharmacological optimization of orally bioavailable 2- pyridone-containing peptidomimetics. J.Med.Chem.46,4572-4585.
10. Dragovich P.S., Prins T.J., Zhou R., Johnson T.O., Hua Y., Luu H.T., Sakata S.K., Brown E.L., Maldonado F.C., Tuntland T., Lee C.A., Fuhrman S.A., Zalman L.S., Patick A.K., Matthews D.A., Wu E.Y., Guo M., Borer B.C., Nayyar N.K., Moran T., Chen L., Rejto P.A., Rose P.W., Guzman M.C., Dovalsantos E.Z., Lee S., McGee K., Mohajeri M., Liese A., Tao J., Kosa M.B., Liu B., Batugo M.R., Gleeson J.P., Wu Z.P., Liu J., Meador J.W., Ferre R.A. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics. J. Med. Chem. 2003, 46:4572-4585.
11. Duintjer Tebbens, R.J.,Pallansch,M.A.,Chumakov,K.M.,Halsey,N.A.,Hovi,T.,Minor, P.D., Modlin,J.F.,Patriarca,P.A.,Sutter,R.W.,Wright,P.F.,Wassilak,S.G.F.,Cochi, S.L., Kim,J.-H.,Thompson,K.M.,inpress. Expert review on poliovirus immunity and transmission. Risk Anal. http://dx.doi.org/10.1111/risa.12022.
12. Duintjer Tebbens, R.J., Pallansch, M.A., Chumakov, K.M., Halsey, N.A., Hovi, T., Minor, P.D., Modlin, J.F., Patriarca, P.A., Sutter, R.W., Wright, P.F., Wassilak, S.G.F., Cochi, S.L., Kim, J.-H., Thompson, K.M., in press. Expert review on poliovirus immunity and transmission. Risk Anal. http://dx.doi.org/10.1111/risa.12022.
13. Hogle, J.M.,Chow,M.,Filman,D.J.,1985.Three-dimensional structure of poliovirus at 2.9 Aresolution.Science 229,1358-1365.
14. Hogle J.M., Chow M., Filman D.J. Three-dimensional structure of poliovirus at 2.9 A resolution. Science 1985, 229:1358-1365.
15. Kaiser, L.,Crump,C. E.,Hayden,F.G.,2000.In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses.Antiviral Res. 47,215-220.
16. Kaiser L., Crump C.E., Hayden F.G. In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses. Antiviral Res. 2000, 47:215-220.
17. Liu, H.-M.,Roberts,J.A.,Moore,D.,Anderson,B.,Pallansch,M.A.,Pevear,D.C.,Collett, M.S., Oberste,M.S.,2012.Characterization of poliovirus variants selected for resistance to the antiviral compound V-073.Antimicrob.Agents Chemother.56, 5568-5574.
18. Liu H.-M., Roberts J.A., Moore D., Anderson B., Pallansch M.A., Pevear D.C., Collett M.S., Oberste M.S. Characterization of poliovirus variants selected for resistance to the antiviral compound V-073. Antimicrob. Agents Chemother. 2012, 56:5568-5574.
19. McKinlay, M.A.,Pevear,D.C.,Rossmann,M.G.,1992.Treatment of the picornavirus common cold by in hibitors of viral uncoating and attachment.Annu.Rev. Microbiol. 46,635-654.
20. McKinlay M.A., Pevear D.C., Rossmann M.G. Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment. Annu. Rev. Microbiol. 1992, 46:635-654.
21. Minor, P.,2009.Vaccine-derived poliovirus (VDPV):impact on poliomyelitis eradication. Vaccine 27,2649-2652.
22. Minor P. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 2009, 27:2649-2652.
23. National Research Council, 2006. Exploring the Role of Antiviral Drugs in the Eradication of Polio. The National Academies Press,Washington,DC. Oberste, M.S.,Moore,D.,Anderson,B.,Pallansch,M.A.,Pevear,D.C.,Collett,M.S., 2009. In vitro antiviral activity of V-073 against polioviruses.Antimicrob. Agents Chemother. 53,4501-4503.
24. National Research Council Exploring the Role of Antiviral Drugs in the Eradication of Polio 2006, The National Academies Press, Washington, DC.
25. Patick, A.K.,2006.Rhinovirus chemotherapy.Antiviral Res.71,391-396.
26. Oberste M.S., Moore D., Anderson B., Pallansch M.A., Pevear D.C., Collett M.S. In vitro antiviral activity of V-073 against polioviruses. Antimicrob. Agents Chemother. 2009, 53:4501-4503.
27. Patick, A.K.,Binford,S.L.,Brothers,M.A.,Jackson,R.L.,Ford,C. E.,Diem,M.D., Maldonado, F.,Dragovich,P.S.,Zhou,R.,Prins,T.J.,Fuhrman,S.A.,Meador,J.W., Zalman, L.S.,Matthews,D.A.,Worland,S.T.,1999.In vitro antiviral activity of AG7088, apotent in hibitor of human rhinovirus 3Cprotease.Antimicrob. Agents Chemother. 43,2444-2450.
28. Patick A.K. Rhinovirus chemotherapy. Antiviral Res. 2006, 71:391-396.
29. Patick, A.K.,Brothers,M.A.,Maldonado,F.,Binford,S.,Maldonado,O.,Fuhrman,S., Petersen, A.,Smith 3rd,G.J.,Zalman,L.S.,Burns-Naas,L.A.,Tran,J.Q.,2005.In vitro antiviral activity and single-dose pharmacokinetics in humans of anovel, orally bioavailable in hibitor of human rhinovirus 3Cprotease.Antimicrob. Agents Chemother. 49,2267-2275.
30. Patick A.K., Binford S.L., Brothers M.A., Jackson R.L., Ford C.E., Diem M.D., Maldonado F., Dragovich P.S., Zhou R., Prins T.J., Fuhrman S.A., Meador J.W., Zalman L.S., Matthews D.A., Worland S.T. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 1999, 43:2444-2450.
31. Pevear, D.C.,Fancher,M.J.,Felock,P.J.,Rossmann,M.G.,Miller,M.S.,Diana,G., Treasurywala, A.M.,McKinlay,M.A.,Dutko,F.J.,1989.Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors. J.Virol.63,2002-2007.
32. Patick A.K., Brothers M.A., Maldonado F., Binford S., Maldonado O., Fuhrman S., Petersen A., Smith G.J., Zalman L.S., Burns-Naas L.A., Tran J.Q. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 2005, 49:2267-2275.
33. Pevear, D.C.,Tull,T.M.,Seipel,M. E.,Groarke,J.M.,1999.Activity of pleconaril against enteroviruses. Antimicrob.Agents Chemother.43,2109-2115.
34. Pevear D.C., Fancher M.J., Felock P.J., Rossmann M.G., Miller M.S., Diana G., Treasurywala A.M., McKinlay M.A., Dutko F.J. Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors. J. Virol. 1989, 63:2002-2007.
35. Prichard, M.N.,Aseltine,K.R.,Shipman,C.J.,1993.MacSynergy IIUser's Manual. University of Michigan,Ann Arbor,MI.
36. Pevear D.C., Tull T.M., Seipel M.E., Groarke J.M. Activity of pleconaril against enteroviruses. Antimicrob. Agents Chemother. 1999, 43:2109-2115.
37. Prichard, M.N.,Shipman Jr.,C.,1990.Athree-dimensional model to analyze drug- drug interactions. Antiviral Res.14,181-205.
38. Prichard M.N., Aseltine K.R., Shipman C.J. MacSynergy II User's Manual 1993, University of Michigan, Ann Arbor, MI.
39. Sutter, R.W.,Kew,O.M.,Cochi,S.L.,2008.Poliovirus vaccine-live. In:Plotkin,S.A., Orenstein, W.A.,of fit,P.A.(Eds.),Vaccines Saunders. Elsevier,pp.631-686.
40. Prichard M.N., Shipman C. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 1990, 14:181-205.
41. Thibaut, H.J.,Leyssen,P.,Puerstinger,G.,Muigg,A.,Neyts,J.,DePalma,A.M.,2011. To wards the design of combination therapy for the treatment of enterovirus infections. Antiviral Res.90,213-217.
42. Sutter R.W., Kew O.M., Cochi S.L. Poliovirus vaccine-live. Vaccines Saunders 2008, Elsevier, pp. 631-686. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
43. Watson, K.G.,Brown,R.N.,Cameron,R.,Chalmers,D.K.,Hamilton,S.,Jin,B., Krippner, G.Y.,Luttick,A.,McConnell,D.B.,Reece,P.A.,Ryan,J.,Stanislawski,P.C., Tucker, S.P.,Wu,W.Y.,Barnard,D.L.,Sidwell,R.W.,2003.Anorally bioavailable oxime ether capsid binder with potent activity against human rhinovirus.J. Med. Chem.46,3181-3184.
44. Thibaut H.J., Leyssen P., Puerstinger G., Muigg A., Neyts J., De Palma A.M. Towards the design of combination therapy for the treatment of enterovirus infections. Antiviral Res. 2011, 90:213-217.
45. Watson K.G., Brown R.N., Cameron R., Chalmers D.K., Hamilton S., Jin B., Krippner G.Y., Luttick A., McConnell D.B., Reece P.A., Ryan J., Stanislawski P.C., Tucker S.P., Wu W.Y., Barnard D.L., Sidwell R.W. An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. J. Med. Chem. 2003, 46:3181-3184.